

Table SI. Meta-analysis of effect events between pembrolizumab plus chemotherapy group and chemotherapy alone group.

Effect	Studies included (Refs.)	Pe+C, n	C, n	HeterogeneityI ² , %	Meta-analysis			
					Model	OR	95%CI	P-value
Treatment-related adverse events leading to discontinuation (Fig. 6A)	(15-18)	395	294	0	Fixed	1.46	1.23-1.73	<0.001
Grade 3-5 treatment-related adverse events occurred (Fig. 6B)	(15-18)	661	581	12	Fixed	1.31	1.10-1.54	0.002
Immune-mediated adverse events and infusion reactions (Fig. 6C)	(15,16)	74	23	0	Fixed	3.76	2.28-6.20	<0.001
Succumbed to drug-related events (Fig. 6D)	(15-18)	18	21	22	Fixed	0.85	0.46-1.59	0.62
Died of immune-mediated events (Fig. 6E)	(15,18)	2	2	0	Fixed	0.99	0.14-7.04	0.99
Treatment-related adverse events (Fig. 6F)	(15-18)	1452	1433	74	Random	0.93	0.26-3.39	0.92

Fixed, fixed-effects model; Pe, pembrolizumab; C, chemotherapy; OR, odds ratio; CI, confidence interval.